241 related articles for article (PubMed ID: 37200041)
1. Interaction between mucus layer and gut microbiota in non-alcoholic fatty liver disease: Soil and seeds.
Zhang B; Li J; Fu J; Shao L; Yang L; Shi J
Chin Med J (Engl); 2023 Jun; 136(12):1390-1400. PubMed ID: 37200041
[TBL] [Abstract][Full Text] [Related]
2. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.
Koopman N; Molinaro A; Nieuwdorp M; Holleboom AG
Aliment Pharmacol Ther; 2019 Sep; 50(6):628-639. PubMed ID: 31373710
[TBL] [Abstract][Full Text] [Related]
3. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives.
Hu H; Lin A; Kong M; Yao X; Yin M; Xia H; Ma J; Liu H
J Gastroenterol; 2020 Feb; 55(2):142-158. PubMed ID: 31845054
[TBL] [Abstract][Full Text] [Related]
4. Gut microbiome and non-alcoholic fatty liver disease.
Purohit A; Alam MJ; Kandiyal B; Shalimar ; Das B; Banerjee SK
Prog Mol Biol Transl Sci; 2022; 191(1):187-206. PubMed ID: 36270678
[TBL] [Abstract][Full Text] [Related]
5. Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies.
Ebrahimzadeh Leylabadlo H; Ghotaslou R; Samadi Kafil H; Feizabadi MM; Moaddab SY; Farajnia S; Sheykhsaran E; Sanaie S; Shanehbandi D; Bannazadeh Baghi H
Eur J Clin Microbiol Infect Dis; 2020 Apr; 39(4):613-627. PubMed ID: 31828683
[TBL] [Abstract][Full Text] [Related]
6. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
Suk KT; Kim DJ
Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
[TBL] [Abstract][Full Text] [Related]
7. Non-alcoholic fatty liver disease and gut microbial dysbiosis- underlying mechanisms and gut microbiota mediated treatment strategies.
Jayachandran M; Qu S
Rev Endocr Metab Disord; 2023 Dec; 24(6):1189-1204. PubMed ID: 37840104
[TBL] [Abstract][Full Text] [Related]
8. Targeting nonalcoholic fatty liver disease via gut microbiome-centered therapies.
Koning M; Herrema H; Nieuwdorp M; Meijnikman AS
Gut Microbes; 2023; 15(1):2226922. PubMed ID: 37610978
[TBL] [Abstract][Full Text] [Related]
9. Fighting Fatty Liver Diseases with Nutritional Interventions, Probiotics, Symbiotics, and Fecal Microbiota Transplantation (FMT).
Nobili V; Mosca A; Alterio T; Cardile S; Putignani L
Adv Exp Med Biol; 2019; 1125():85-100. PubMed ID: 30578461
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view.
Chen HT; Huang HL; Li YQ; Xu HM; Zhou YJ
World J Gastroenterol; 2020 Apr; 26(16):1901-1911. PubMed ID: 32390701
[TBL] [Abstract][Full Text] [Related]
11. Mechanistic and physiological approaches of fecal microbiota transplantation in the management of NAFLD.
Gupta M; Krishan P; Kaur A; Arora S; Trehanpati N; Singh TG; Bedi O
Inflamm Res; 2021 Jul; 70(7):765-776. PubMed ID: 34212214
[TBL] [Abstract][Full Text] [Related]
12. Effect of Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial.
Xue L; Deng Z; Luo W; He X; Chen Y
Front Cell Infect Microbiol; 2022; 12():759306. PubMed ID: 35860380
[TBL] [Abstract][Full Text] [Related]
13. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease.
Miura K; Ohnishi H
World J Gastroenterol; 2014 Jun; 20(23):7381-91. PubMed ID: 24966608
[TBL] [Abstract][Full Text] [Related]
14. Gut-liver axis, nutrition, and non-alcoholic fatty liver disease.
Kirpich IA; Marsano LS; McClain CJ
Clin Biochem; 2015 Sep; 48(13-14):923-30. PubMed ID: 26151226
[TBL] [Abstract][Full Text] [Related]
15. New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease.
Hartmann P; Schnabl B
Semin Liver Dis; 2021 Jan; 41(1):87-102. PubMed ID: 33957682
[TBL] [Abstract][Full Text] [Related]
16. The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD.
Huang W; Kong D
Biomed Pharmacother; 2021 Mar; 135():111235. PubMed ID: 33561650
[TBL] [Abstract][Full Text] [Related]
17. The Role of Gut-Derived Lipopolysaccharides and the Intestinal Barrier in Fatty Liver Diseases.
An L; Wirth U; Koch D; Schirren M; Drefs M; Koliogiannis D; Nieß H; Andrassy J; Guba M; Bazhin AV; Werner J; Kühn F
J Gastrointest Surg; 2022 Mar; 26(3):671-683. PubMed ID: 34734369
[TBL] [Abstract][Full Text] [Related]
18. Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia.
Xue L; He J; Gao N; Lu X; Li M; Wu X; Liu Z; Jin Y; Liu J; Xu J; Geng Y
Sci Rep; 2017 Mar; 7():45176. PubMed ID: 28349964
[TBL] [Abstract][Full Text] [Related]
19. Prebiotics and Probiotics: Therapeutic Tools for Nonalcoholic Fatty Liver Disease.
Mijangos-Trejo A; Nuño-Lambarri N; Barbero-Becerra V; Uribe-Esquivel M; Vidal-Cevallos P; Chávez-Tapia N
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834367
[TBL] [Abstract][Full Text] [Related]
20. Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity?
Aron-Wisnewsky J; Warmbrunn MV; Nieuwdorp M; Clément K
Gastroenterology; 2020 May; 158(7):1881-1898. PubMed ID: 32044317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
